CymoGen Dx, LLC, a genomic diagnostic technology company, provides genomic-based reagents and fluorescent in-situ hybridization probes research products and solutions for the diagnosis and monitoring of cancers and human genetic disorders for clinical, biopharmaceutical, and research customers. It engages in the development, manufacture, and application of fluorescence-based DNA detection technology. The company provides tools for identifying genomic aberrations in cancer cells found in tissue and bone marrow specimens. CymoGen Dx, LLC was formerly known as CymoGen, LLC. The company was incorporated in 2010 and is based in New Windsor, New York.